Exonox’ platform technology could deliver patient stratification and clinical trial enrichment
Exhibitor: EXONOX BIOSCIENCES, INC.
Booth No.: N604
Taipei, Taiwan, July 28, 2023 – Biomarker Discovery company Exonox Biosciences, Inc (ENB). today announced its core biomarker discovery platform which it has led to development of Exonox®TNBC, a panel of exosomal biomarkers for the assessment of Triple Negative Breast Cancer (TNBC) differential diagnosis with a simple blood test as an assistant to current imaging and invasive tissue biopsy approach and Exonox®Renal, a dual circulating biomarker ELISA assay, an early detection of renal function decline for patients with or without diabetics (DM).
Exonox Biosciences’ prestige platform is able to deliver:
- Patient Data Driven Prognostic and Druggable Target Discovery
- Biomarker profile discovered directly from patients of target disease with proper disease control; not in-silico, in-vitro, ex-vivo or nonhuman subjects.
- Multidisciplinary Pipeline Approach
- Biomarker profile can serve multiple pipelines’ development from diagnostic assay to potential therapeutic targets.
- Novel Target Discovery Strategy
- Unsupervised approach analysis with cutting edge tools to uncover potentially novel and druggable target than supervised approach with limitations.
- Full Patient’s Medical Prognostic Database
- Full spectrum of patient database with longitudinal tracking of pathogenesis from target patient group.
Dr. Wei-Min Wang, CEO and founder of Exonox Biosciences commented: "If the disease biomarkers cannot be detected, the disease cannot be improved! By using our platform, we can help to save resources, money, and time by accelerating the drug development through the thorough understanding of biology and mode of action of disease and how it responses to the therapy. It also is likely to become a more common practice in clinical trials.
More Exhibitor's Press Release
- Comparison of Maglev Centrifugal Pump and Quaternary Diaphragm Pump Effects on mRNA encapsulated LNP LEVITRONIX GMBH TAIWAN BRANCH / 2023-08-02
- Evolution of Upstream Bioprocessing for Viral Vector Production LEVITRONIX GMBH TAIWAN BRANCH / 2023-08-02
- TFF Shear Stress Investigations on Levitronix® Single-Use Centrifugal Pumps LEVITRONIX GMBH TAIWAN BRANCH / 2023-08-02
- Golden Biotech will showcase at BIO Asia 2023 and hold a seminar GOLDEN BIOTECHNOLOGY CORP. / 2023-07-30
- Life Science FVG Cluster CLUSTER SCIENZE DELLA VITA DEL FRIULI VENEZIA GIULIA - POLO TECNOLOGICO ALTO ADRIATICO ANDREA GALVANI / 2023-07-29
- Taiwan FDA granted the API Market License of Ponatinib HCI "GBC" GENOVIOR BIOTECH CORP. / 2023-07-29
- Co-development partner wanted for the following injection projects GENOVIOR BIOTECH CORP. / 2023-07-29
- EU Partners submit MAA to several EU member states, and expect EU GMP site audit conducted in 2024. GENOVIOR BIOTECH CORP. / 2023-07-29
- IKG Medtech Co., Ltd. "IKG Long-distance Reablement Service" and "IKG Leg Power King" integrate the IKG MEDTECH CO., LTD. / 2023-07-29
- NYCU's Anivance AI Revolutionizes Animal Testing Models with Biomimetic Organs-on-Chips Technology! NYCU-GUAN-YU CHEN / 2023-07-28
- As a HUB of European medical industry, Italy participates in Bio Asia 2023 ITALIAN ECONOMIC, TRADE AND CULTURAL PROMOTION OFFICE IN TAIPEI TRADE SECTION / 2023-07-27
- Exonox has completed the prototype kit for non-invasive monitoring of renal function decline in DN EXONOX BIOSCIENCES, INC. / 2023-07-27
- HANCHORBIO ANNOUNCES TFDA IND APPROVAL FOR HCB101 TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES HANCHORBIO INC. / 2023-07-26
- Labtech pioneers compliant airflow monitoring and control solutions for laboratories LABTECH EQUIPMENT CORP. / 2023-07-26
- Labtech offers comprehensive solutions for laboratory ventilation furniture and equipment LABTECH EQUIPMENT CORP. / 2023-07-26
- Labtech x TRIPOWER Showcase Lab Design and Planning Competence LABTECH EQUIPMENT CORP. / 2023-07-26
- Open Lab Day : 16th/17th/18th August 2023 MALVERN PANALYTICAL / 2023-07-26
- NanoSight Pro Launch: Characterizing Bionanomaterials has never been so quick, easy and accurate! MALVERN PANALYTICAL / 2023-07-26
- Malvern Panalytical Taiwan offers full-fledged application and sales support, even for particle size MALVERN PANALYTICAL / 2023-07-26
- Dangerous high rate myopia, Eyemikan Myopia Services to protect the occurrence of critical vision. EYEMIKAN BIOTECH INC. / 2023-07-25